Discover PT-141 peptide, also known as bremelanotide (brand name Vyleesi), the first and only FDA-approved melanocortin receptor agonist specifically indicated for treating acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors such as sildenafil that primarily target blood flow, PT-141 works centrally in the brain by activating melanocortin-4 receptors (MC4R) to support natural sexual desire, motivation, and arousal pathways.
This cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH), a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), offers a unique, on-demand approach for those seeking to address low libido that causes distress. Clinical data from the Phase 3 RECONNECT trials demonstrated statistically significant improvements in sexual desire scores and reductions in related distress compared to placebo.
Key Benefits of PT-141 Peptide
• Supports increased sexual desire and reduced distress associated with HSDD in eligible premenopausal women.
• Central mechanism of action targeting the hypothalamus and limbic system rather than peripheral vascular effects.
• On-demand subcutaneous use (typically 1.75 mg via autoinjector or equivalent), administered at least 45 minutes before anticipated sexual activity.
• Potential complementary option in research and clinical contexts for sexual function support (note: approved indication is specific; other uses are off-label).
• Distinct from traditional ED medications, making it of interest for cases involving desire rather than solely erectile mechanics.
How PT-141 Works
PT-141 (bremelanotide) binds melanocortin receptors in the central nervous system. This activation influences dopaminergic reward and sexual motivation circuits, helping facilitate the subjective experience of desire and arousal. Effects are typically noticed within about 45 minutes, with transient physiological changes (including modest blood pressure increases and heart rate decreases) that generally resolve within 12 hours.
Recommended Considerations for Use
Standard FDA-approved dosing for Vyleesi is 1.75 mg subcutaneously as needed, no more than once per 24 hours and no more than 8 doses per month. Always follow guidance from a qualified healthcare provider. PT-141 is not approved for postmenopausal women, men, or for improving sexual performance in the absence of HSDD meeting specific criteria. Consult a physician to determine appropriateness, especially if you have cardiovascular concerns, uncontrolled hypertension, or other medical conditions.
Common Side Effects
The most frequently reported side effects include nausea (often the most common, occurring in a substantial portion of trial participants and sometimes transient or manageable), flushing, headache, injection-site reactions (pain, redness, bruising), and vomiting. Transient increases in blood pressure and decreases in heart rate can occur. Focal hyperpigmentation has been noted with more frequent use. Discuss risks, benefits, and monitoring with a healthcare professional.
Important: This product description is for informational purposes. PT-141 / bremelanotide (Vyleesi) is a prescription medication. Research peptides or compounded versions may differ in regulation, purity, and legal status. Always source from reputable channels and use only under medical supervision. Individual results vary.
Shop high-quality PT-141 peptide for research or clinician-guided applications and experience a brain-first approach to supporting sexual wellness. Order today and prioritize verified, tested materials.
Ronald –
All I say is my wife is very happy.